Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Acquired via Acer Therapeutics (November 2023)
Indications
Vascular Ehlers-Danlos syndrome (VEDS)(Phase 3)
Status note Phase 3 DiSCOVER trial (event-driven, 150 patients planned, celiprolol vs placebo) ongoing; recruitment restarted mid-2024 with 66 enrolled as of June 30, 2026. Orphan Drug Designation (2015); prior NDA received CRL requesting an adequate and well-controlled trial.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.